Krystal Biotech (NASDAQ:KRYS) reported third-quarter 2026 revenue growth driven by continued adoption of its VYJUVEK ...

Krystal Biotech delivered a clean commercial beat in the third quarter. It earned $2.05 per share on revenue of $127.34 million, topping the $1.84 consensus by 11.4% and the $124.65 million revenue ...

Krystal Biotech (KRYS) delivered earnings and revenue surprises of +11.41% and +2.16%, respectively, for the quarter ended ...

<?xml encoding="utf-8" ?> Krystal Biotech KRYS reported third-quarter financial results on Monday. The transcript from the ...

Anthropic bought Mithril Medicine, a one-person biotech that ran a drug program with Claude, a sign its market may reach ...

The Treasury Department’s proposed restrictions on U.S. investment in Chinese biopharma collide with Beijing’s new export ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

Etiome, Cellarity and Empress Therapeutics are being combined into one new AI-aided drugmaker claiming to possess the ability ...

Exploratory research in mSystems finds broader small-bowel gene-expression changes in ISO than in methanogen overgrowth or ...

The company is having a great year.

By Karen Roman Darwin Biotech said it presented data from its placebo-controlled Phase 1 study of ALT001 to treat amyotrophic ...

Moderna gave investors a scare as its stock plunged on Thursday. But it's still one of the hottest biotechs this year. And it's hardly alone – the sector is on a roll and looks poised for more gains.